Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026

Rhea-AI Summary

Kyverna Therapeutics (NASDAQ: KYTX) will present new neuroimmunology data at the American Academy of Neurology (AAN) Annual Meeting, April 18-22, 2026 in Chicago.

Oral sessions include primary analysis from the registrational KYSA-8 trial in stiff person syndrome showing statistically significant clinical benefit and updated KYSA-6 Phase 2 results in generalized myasthenia gravis. Multiple posters cover real-world outcomes and Phase 3 design.

Key Figures

Meeting dates: April 18–22, 2026 KYSA-8 phase: Phase 2 KYSA-6 phase: Phase 2 +5 more

8 metrics

Meeting dates April 18–22, 2026 AAN Annual Meeting timing

KYSA-8 phase Phase 2 Pivotal registrational SPS trial

KYSA-6 phase Phase 2 Generalized myasthenia gravis study update

KYSA-6 next stage Phase Three Planned randomized controlled gMG study design

Single dose 1 dose Goal of durable, drug-free remission with single miv-cel treatment

Timed walk measure 25-foot walk Outcome measure in SPS natural history study

Price move 10.6% Pre-news 24h price change for KYTX

52-week range $1.78–$13.67 52-week low and high before this news

Market Reality Check

Price: $8.39 Vol: Volume 546,123 is slightl...

normal vol

$8.39 Last Close

Volume Volume 546,123 is slightly below 20-day average 582,814, suggesting no unusual trading activity. normal

Technical Price $8.39 is trading above 200-day MA at $5.84, indicating strength versus longer-term trend.

Peers on Argus

KYTX gained 10.6% while several high-affinity biotech peers (e.g., CABA, CRBU, E...

1 Up

KYTX gained 10.6% while several high-affinity biotech peers (e.g., CABA, CRBU, ELTX, NTHI) showed mixed to negative moves, pointing to a stock-specific reaction rather than a sector-wide move.

Historical Context

5 past events · Latest: Mar 03 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 03	Investor conferences	Neutral	-5.8%	Participation in March 2026 investor conferences and fireside chat/webcast.
Feb 24	Board appointments	Positive	+0.5%	Added directors with capital-markets and clinical development expertise.
Feb 03	CTO appointment	Neutral	+0.0%	Hired experienced cell and gene therapy manufacturing executive as CTO.
Jan 12	Corporate update	Positive	-1.1%	Outlined 2026 priorities, BLA timing, new IND, and strengthened cash runway.
Jan 05	Conference presentation	Neutral	-7.3%	Announcement of CEO presentation at J.P. Morgan Healthcare Conference.

Pattern Detected

Recent corporate and conference-related news has produced modest and sometimes negative price reactions, even when updates appeared strategically positive.

Recent Company History

Over the past months, Kyverna’s news flow centered on corporate positioning and autoimmune CAR T progress. A Jan 12, 2026 corporate update highlighted plans to file a BLA for SPS in 1H 2026, Phase 3 enrollment in gMG, and a $105M follow-on offering extending cash to 2028, yet the stock fell 1.08%. Board and CTO appointments in February saw flat-to-slightly-positive moves. Today’s AAN data disclosures fit the ongoing narrative of advancing miv-cel and KYV-101 in SPS and gMG.

Market Pulse Summary

This announcement showcases Kyverna’s progress in neuroimmunology, featuring pivotal KYSA-8 stiff pe...

Analysis

This announcement showcases Kyverna’s progress in neuroimmunology, featuring pivotal KYSA-8 stiff person syndrome data and updated KYSA-6 Phase 2 results in generalized myasthenia gravis at AAN 2026. It builds on prior disclosures about miv-cel and KYV-101 and outlines the path toward a Phase Three gMG study versus standard-of-care. Investors may watch for detailed efficacy, safety, and durability metrics, as well as how these programs integrate with the broader 2026 strategic and regulatory plans.

Key Terms

car t-cell therapy, cd19, chimeric antigen receptor, registrational trial, +4 more

8 terms

car t-cell therapy medical

"Miv-cel CD19 CAR T-Cell Therapy Shows Efficacy and Safety in Stiff Person..."

Car T-cell therapy is a medical treatment that uses a patient’s own immune cells, modified in a lab to better recognize and attack cancer cells. It is considered a breakthrough because it offers potentially long-lasting effects for certain types of cancer. For investors, its development and approval can signal advances in healthcare innovation and potential growth opportunities in the biotech sector.

cd19 medical

"Miv-cel CD19 CAR T-Cell Therapy Shows Efficacy and Safety in Stiff Person..."

CD19 is a protein found on the surface of most B cells, a type of immune cell; think of it as a distinctive nametag that helps identify and track these cells. It matters to investors because many cancer and autoimmune treatments, diagnostics, and lab tests are designed to target or detect CD19—so advances, approvals, or setbacks in CD19‑focused therapies can directly affect drug pipelines, regulatory value, and potential revenue for healthcare companies.

chimeric antigen receptor medical

"a Fully Human CD19 Chimeric Antigen Receptor (CAR) T-cell Therapy in..."

A chimeric antigen receptor is an engineered protein added to a patient’s immune cells that gives them a new, specific ability to recognize and attack cells carrying a particular marker (antigen) — like equipping police with a facial‑recognition app to find a suspect. For investors, CARs are the core technology behind targeted cell therapies: their clinical success, manufacturing complexity, safety profile, and regulatory approval determine treatment market potential, development costs, and company value.

registrational trial medical

"primary analysis from KYSA-8 registrational trial in stiff person syndrome..."

A registrational trial is the large, definitive clinical study designed to provide the evidence regulators need to decide whether a new drug or medical product can be approved for sale. Think of it as the final exam for a treatment: passing it can unlock widespread market access and potential revenues, while failing it can sharply reduce a product’s commercial prospects and raise investment risk.

open-label medical

"an Open-label, Single-arm, Multicenter Study of KYV-101, a Fully Human..."

Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.

single-arm medical

"an Open-label, Single-arm, Multicenter Study of KYV-101, a Fully Human..."

A single-arm study is a clinical trial that gives all participants the same treatment and does not include a separate comparison group or placebo. Think of it like testing a new recipe by serving it to diners without offering a control dish — you can see how people respond, but you can’t directly compare results to another option. For investors, single-arm trials can speed development and reduce cost but leave more uncertainty about how a treatment stacks up against existing therapies and how regulators will view the evidence.

randomized, controlled medical

"a Global Open-label, Randomized, Controlled Study of KYV-101, a Fully..."

A randomized, controlled study is a type of clinical test where participants are assigned by chance to different groups—one gets the treatment and another (the control) gets a placebo or standard care—so results can be compared fairly. Like flipping a coin to avoid favoritism, this design reduces bias and gives investors more trustworthy evidence about whether a medicine or intervention actually works and is safe, which influences regulatory approval, market potential, and company value.

standard-of-care (soc) medical

"Versus Ongoing Standard-of-Care (SOC) Immunosuppressive Therapy in..."

The standard-of-care (SOC) is the accepted, routine medical treatment or procedure that most doctors use for a given condition; it serves as the baseline against which new therapies are judged. For investors, SOC matters because a new drug or device must typically outperform or match the SOC to win regulatory approval, gain market adoption, and secure reimbursement—think of SOC as the default product consumers expect, and new offerings must prove they’re better or more cost-effective to capture market share.

AI-generated analysis. Not financial advice.

Late-breaking oral presentation to feature primary analysis from KYSA-8 registrational trial in stiff person syndrome (SPS)

Oral presentation on updated KYSA-6 Phase 2 data in generalized myasthenia gravis (gMG)

EMERYVILLE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced multiple abstracts selected for presentation at the American Academy of Neurology (AAN) Annual Meeting, taking place from April 18-22, 2026, in Chicago, IL.

“Our presence at AAN marks an important milestone for Kyverna as we build upon miv-cel’s potential to redefine the treatment paradigm in both stiff person syndrome and myasthenia gravis,” said Warner Biddle, Chief Executive Officer of Kyverna Therapeutics. “The primary analysis from our SPS registrational trial expands on our previously reported positive topline results, which demonstrated statistically significant clinical benefit across all primary and secondary endpoints, including reversing progressive disability. We will also present updated Phase 2 results in myasthenia gravis, seeking to advance our goal of delivering durable, drug-free, disease-free remission with a single dose.”

Oral Presentations:
Title: Miv-cel CD19 CAR T-Cell Therapy Shows Efficacy and Safety in Stiff Person Syndrome in a Pivotal, Multicenter, Phase 2 Study (KYSA-8)
Presenter: Amanda Piquet, M.D., FAAN, University of Colorado Anschutz School of Medicine
Date & Time: Tuesday, April 21, 2026, 6:27 PM CT

Title: Update on the Phase Two Portion of KYSA-6, an Open-label, Single-arm, Multicenter Study of KYV-101, a Fully Human CD19 Chimeric Antigen Receptor (CAR) T-cell Therapy in Generalized Myasthenia Gravis (gMG)
Presenter: Srikanth Muppidi, M.D., Stanford Medicine
Date & Time: Monday, April 20, 2026, 1:48 PM CT

Poster Presentations:
Title: A Multicenter, Real-world Natural History Study on Timed 25-Foot Walk Outcome Measures in Stiff Person Syndrome
Presenter: Scott Newsome, D.O., Johns Hopkins Medicine
Date & Time: Monday, April 20, 2026, 8:00 AM CT

Title: Design of Phase Three of KYSA-6, a Global Open-label, Randomized, Controlled Study of KYV-101, a Fully Human CD19 Chimeric Antigen Receptor (CAR) T-cell Therapy, Versus Ongoing Standard-of-Care (SOC) Immunosuppressive Therapy in Generalized Myasthenia Gravis (gMG)
Presenter: Srikanth Muppidi, M.D., Stanford Medicine
Date & Time: Tuesday, April 21, 2026, 5:00 PM CT

About Stiff Person Syndrome (SPS)
SPS is a rare, progressive neurologic autoimmune disease characterized by muscle stiffness and painful muscle spasms, impacting mobility and gait. Stiffness, rigidity, and spasms in the torso, arms, and legs lead to progressive disability causing up to 80% of patients to lose mobility^1-3. SPS has been shown to lead to permanent disability and increased risk of mortality³. Most patients with SPS have antibodies to glutamic acid decarboxylase 65 (GAD65) or the glycine receptor, which disrupt normal inhibitory neurotransmission, contributing to the hallmark symptoms of SPS. There are currently no FDA-approved treatments for SPS. Current treatment options include symptomatic treatments, off-label immunotherapies, such as intravenous immunoglobulin (IVIg), rituximab and plasmapheresis, as well as supportive care and physical, speech, occupational, and psychiatric therapy; however, the majority of patients have inadequate or no response to these treatment options. An estimated 6,000 patients are diagnosed with SPS in the United States^4-5.

About Myasthenia Gravis (MG)
Myasthenia gravis is a B-cell and antibody-mediated autoimmune neuromuscular disease that causes muscle weakness and fatigue, and patients may experience difficulty speaking, chewing, swallowing, or breathing. It is caused by autoantibodies produced by B-cells that lead to an immunological attack on critical signaling proteins at the junction between nerve and muscle cells, thereby inhibiting the ability of nerves to communicate properly with muscles. Although symptoms may initially remit, most patients experience progressive disease requiring chronic immunosuppressive therapy. Up to 20% of MG patients experience respiratory crisis at least once in their lives⁶. An estimated 80,000 patients are diagnosed with generalized myasthenia gravis in the United States^7-8.

About miv-cel (mivocabtagene autoleucel, KYV-101)
Miv-cel is a fully human, autologous, CD19-targeting CAR T-cell therapy with CD28 co-stimulation, designed for potency and tolerability, which is under investigation for B-cell-driven autoimmune diseases. With a single administration, miv-cel has potential to achieve deep B-cell depletion and immune system reset to deliver durable drug-free, disease-free remission in autoimmune diseases. 

About Kyverna Therapeutics
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company focused on liberating autoimmune patients through the curative potential of cell therapy. The Company’s lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases. Kyverna is advancing its potentially first-in-class neuroimmunology franchise with its initial indications in stiff person syndrome and myasthenia gravis. The Company is also advancing additional clinical and investigator-sponsored studies, including in multiple sclerosis and rheumatoid arthritis, to inform future priority indications and develop next-generation CAR T platforms to improve access and patient experience. For more information, please visit https://kyvernatx.com.

Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Forward-looking statements in this press release include, without limitation, those related to: Kyverna’s anticipated timing for its presentations at the AAN Annual Meeting and the topics expected to be discussed during such presentations; opportunities related to miv-cel, including miv-cel’s potential to redefine the treatment paradigm in both SPS and myasthenia gravis; the expansion of its previously reported topline data; miv-cel’s potential ability to reverse progressive disability miv-cel’s potential to achieve deep B-cell depletion and immune system reset to deliver durable drug-free, disease-free remission in autoimmune diseases in a single dose; and Kyverna’s potentially first-in-class neuroimmunology franchise. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to market conditions, the possibility that results from prior clinical trials, named-patient access activities and preclinical studies may not necessarily be predictive of future results; the possibility that the FDA or other regulatory agencies may require additional trials or studies to support its intended BLA submission; intellectual property rights; and other factors discussed in the “Risk Factors” section of Kyverna’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that Kyverna has filed or may subsequently file with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release are based on the current expectations of Kyverna’s management team and speak only as of the date hereof, and Kyverna specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact: 
Investors: InvestorRelations@kyvernatx.com 
Media: media@kyvernatx.com 

¹ Rakocevic G, et al. BMC Neurol. 2019;19:1.
² Dalakas MC. Nat Rev Neurol. 2024;20(10):587-601.
³ Duddy ME, Baker MR. Front Neurol Neurosci. 2009;26:147-165.
⁴ Crane PD, et al. Neurology. 2024;103(12):e210078.
⁵ Analysis of 2024 Komodo U.S. Claims Data.
⁶ Claytor B, et al. Muscle Nerve. 2023;68(1):8-19.
⁷ Rodriguez E, et al. Muscle. Nerve. 2024;69(2):166-171.
⁸ Hendricks TM, et al. Am J Opthamol. 2019; 205:99-105. 3. Clarivate DRG Report (2024).

FAQ

What will Kyverna (KYTX) present from the KYSA-8 trial at AAN 2026?

Kyverna will present the primary analysis from KYSA-8, a registrational Phase 2 study in stiff person syndrome. According to the company, the analysis expands on previously reported positive topline results showing statistically significant clinical benefit across primary and secondary endpoints.

When and where will Kyverna present updated KYSA-6 Phase 2 data for gMG (KYTX)?

The KYSA-6 Phase 2 update will be presented on Monday, April 20, 2026 at 1:48 PM CT in Chicago. According to the company, the oral presentation covers updated data for KYV-101 in generalized myasthenia gravis.

What clinical endpoints did Kyverna say improved in the KYSA-8 stiff person syndrome study?

The company reported statistically significant clinical benefit across all primary and secondary endpoints, including reversal of progressive disability. According to the company, these topline results indicate measurable clinical improvement in treated patients.

Will Kyverna present any posters at AAN 2026 related to real-world or trial design?

Yes. Kyverna will present posters on a real-world timed 25-foot walk natural history study and on the Phase 3 design for KYSA-6. According to the company, these posters address outcome measures and global randomized study planning.

Which presenters will deliver Kyverna's oral presentations at AAN 2026 for KYTX?

Presenters include Amanda Piquet, M.D., for the KYSA-8 stiff person syndrome oral and Srikanth Muppidi, M.D., for the KYSA-6 gMG update. According to the company, both are scheduled speakers with named institutions and times.

How does Kyverna describe the clinical goal for its CAR T therapies (KYTX)?

Kyverna describes its goal as delivering durable, drug-free, disease-free remission with a single dose. According to the company, the presentations aim to show clinical efficacy and potential to redefine treatment paradigms in SPS and gMG.